Cure My Disease

Don't miss your cure!

 Log in / Sign up

A wearable vest that listens to the lungs: a new hope for heart failure?

NCT ID NCT05980585

Knowledge-focused Sponsor: Analog Device, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study tests a wearable device called the ADI Cardio Pulmonary Monitoring (CPM) system, designed to track heart failure signs at home. The goal is to see if the device can be easily used by patients and whether its measurements—like breathing rate and chest fluid levels—match real heart failure events. Only two people with advanced heart failure will wear the device daily, and researchers will review their data after the fact to plan a larger, more definitive trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ADI Cardio Pulmonary Monitoring (CPM) wearable device
What this could lead to
If the device proves accurate and easy to use, it could lead to a larger study and eventually a home monitoring tool that helps predict heart failure flare-ups early.
What could go wrong
This is a very early, tiny study with only 2 participants, focused on feasibility rather than health outcomes. The device is not yet used to guide treatment, and its accuracy is only being checked retrospectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

Apr 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: one or more of the following * NYHA Class III-IV HF * NYHA Class II HF patients with elevated BNP levels (BNP\>100 pg per mL) NYHA Class II HF patients with elevated NT-proBNP levels (NT-proBNP\>400 pg per mL) * HF Patients with at least one Worsening HF event (in /out-patient) in past 12 months * HF patients with Acute Renal Failure or Chronic Kidney Disease * HF patients with Chronic Obstructive Pulmonary Disease (COPD) * HF patients currently on 40 mg or more of Furosemide / Exclusion Criteria: * Under age 60 * End Stage Renal Disease * Patients with severe COPD (GOLD stage III or IV) * Limited mobility preventing application of device * Cognitive impairments that would limit the application and proper use of the device * Skin allergies or skin sensitivities to silicone-based adhesives * Pregnancy * Skin breakdown on the left chest or breast area * Not willing to shave chest hair if needed to apply device * No cellular coverage (Patient's Home)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Baptist Health

    Jacksonville Beach, Florida, 32250, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.